Data completeness
3/8 — Basic
CABAZITAXEL (cabazitaxel) by Novartis is inhibitor. Approved for prostate cancer, metastatic castration-resistant prostate cancer, metastatic prostate cancer and 11 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Worked on CABAZITAXEL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.